Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06506916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06506916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 29, 2024
Completion date
March 14, 2028
Enrollment
89 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis, psoriatic arthritis